Drug intelligence / Profile preview

trivalent coronavirus enveloped virus-like particles + aluminum phosphate + E6020

Development stage: Preclinical
Lead developer: Emergent BioSolutions
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

A combination vaccine candidate composed of **trivalent coronavirus enveloped virus-like particles (VLPs)**—representing three coronavirus antigens—along with the adjuvant **aluminum phosphate** and the synthetic **TLR4 agonist E6020**. The virus-like particles mimic the structure of coronaviruses without containing their genetic material, promoting an immune response to the viral spike and envelope proteins. **Aluminum phosphate** acts as an adjuvant, enhancing the humoral (Th2-biased) immune response, mainly by improving antigen uptake and presentation by antigen presenting cells, and stimulating innate immunity via NLRP3 and related inflammatory pathways[1][2][3]. **E6020** is a synthetic lipid A mimetic (related to monophosphoryl lipid A/MPLA) and functions as a toll-like receptor 4 (TLR4) agonist to stimulate stronger innate immune activation, especially promoting Th1-type responses. This composite adjuvant strategy is designed to deliver a balanced Th1/Th2 response, increasing both antibody production and cellular immunity. The vaccine is under research and is intended for the prevention of coronavirus infections.

Other names: trivalent coronavirus virus-like particles + aluminum phosphate + E6020

Targets

ZIKV E (Zika virus envelope protein)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TLR4 (Toll-like receptor 4)RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on trivalent coronavirus enveloped virus-like particles + aluminum phosphate + E6020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on trivalent coronavirus enveloped virus-like particles + aluminum phosphate + E6020.

Explore the full profile